BioLineRx Ltd. (NASDAQ:BLRX) Q1 2020 Earnings Conference Call May 20, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical Development Ella Sorani - Vice President, Research and Development Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the ...

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2019 Earnings Conference Call March 12, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical Development Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx's Fourth Quarter and Full Year 2019 Confere ...

As filed with the U.S. Securities and Exchange Commission on March 12, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY ...

Financial Data and Key Metrics Changes - Research and Development expenses for the nine months ended September 30, 2019, were $15.3 million, an increase of $0.7 million, or 5%, compared to $14.6 million for the same period in 2018 [33] - The company held $30.1 million of cash, cash equivalents, and short-term bank deposits as of September 30, 2019, sufficient to fund operations through significant clinical milestones [34] Business Line Data and Key Metrics Changes - The company is progressing its lead therapeutic candidates BL-8040 and AGI-134 for multiple cancer indications, with BL-8040 being evaluated in several phase 2 and phase 3 clinical trials [7] - BL-8040 has been granted FDA orphan drug designation for pancreatic cancer, acute myeloid leukemia (AML), and stem cell mobilization [9] - The GENESIS trial for stem cell mobilization is ongoing, with top-line results expected in the second half of 2020 [26] Market Data and Key Metrics Changes - The prognosis for pancreatic cancer patients remains poor, with low survival rates, highlighting the urgent need for better therapeutic options [12] - The company is collaborating with Genentech to evaluate BL-8040 in dual combinations for pancreatic and gastric cancers, with results expected in the first half of 2020 [21] Company Strategy and Development Direction - The company aims to partner out BL-8040 for all indications, with a focus on licensing opportunities following upcoming data releases [41] - The strategy includes leveraging data from ongoing trials to attract potential partners, particularly in the larger AML and pancreatic cancer markets [42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data readouts, particularly from the COMBAT/KEYNOTE-202 study, which could be transformational for treatment options in pancreatic cancer [11] - The company plans to provide updates on interim results from the AML study and top-line results from the GENESIS trial in 2020 [38] Other Important Information - The company has been invited to present at the European Society of Medical Oncology, highlighting the significance of the upcoming data [19] - AGI-134 is currently in a Phase 1/2a study, with initial efficacy results expected by the end of 2020 [31] Q&A Session Summary Question: Broader potential commercial profile for BL-8040 - Management is looking to partner out BL-8040 for all indications, with a focus on licensing opportunities following data releases in pancreatic cancer, AML, and stem cell mobilization [41] Question: Differences in patient populations for trials - The patient population in the triple combination study is more homogeneous, which is expected to yield more powerful data compared to earlier studies [48] Question: Inclusion of graphical data in presentations - Management confirmed that graphical representations, including spider plots, will be included in the upcoming presentation to illustrate treatment effects [50]

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2019 Results Conference Call August 6, 2019 10:00 AM ET Company Participants Timothy McCarthy - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - HC Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2019 Conference Call. All participants are at present in a listen-only mode. Following mana ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2019 Results Earnings Conference Call May 14, 2019 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical Development Ella Sorani - VP, Research and Development Conference Call Participants Joe Pantginis - HC Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2019 Conference Call. [Operator Instructions] I would now like to turn the call over ...

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2018 Earnings Conference Call March 27, 2019 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Ella Sorani - VP, Research and Development Conference Call Participants Jason McCarthy - Maxim Joe Pantginis - HC Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2018 Results C ...

As filed with the U.S. Securities and Exchange Commission on March 28, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY ...